Obinutuzumab en combinación con bendamustina para-rituximab refractario indolente linfoma no Hodgkin - segunda línea

Autores
Categoría Resumen estructurado de revisiones sistemáticas
RevistaHTA Database
Año 2014
Cargando información sobre las referencias

RECORD STATUS:

This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

CITATION:

NIHR HSC. Obinutuzumab in combination with bendamustine for rituximab-refractory indolent non-Hodgkin's lymphoma – second line Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014
Epistemonikos ID: f7275cf8bfd1b3299e1f2845319bfcd4960ca848
First added on: Feb 06, 2015